ImmunityBio
IBRX
63 hedge funds and large institutions have $155M invested in ImmunityBio in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 7 closing their positions.
321% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $253K
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
25% more capital invested
Capital invested by funds: $124M → $155M (+$31.3M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 62 → 63 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$991K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$630K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$622K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$238K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Callan Capital
La Jolla,
California
|
-$2.66M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$864K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$328K |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$302K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$205K |
IBRX Hedge Fund Activity: Q3 2016 in Review
63 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2016, worth a combined $155M — up 25% from $124M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IBRX positions and 7 closed out — a net gain of 1 holder — while 22 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.87M. The largest seller was Callan Capital, cutting an estimated $2.66M.
- 63 institutional investors held ImmunityBio (IBRX) as of Q3 2016, up from 62 in Q2 2016.
- Funds reported $155M of ImmunityBio stock for Q3 2016, up 25% quarter-over-quarter.
- 8 funds opened new ImmunityBio positions in Q3 2016 and 7 closed out, a net change of +1 holder.
- The largest ImmunityBio buyer in Q3 2016 was Vanguard Group, an estimated $1.87M added.
- The largest ImmunityBio seller in Q3 2016 was Callan Capital, an estimated $2.66M sold.
Based on aggregated 13F filings for Q3 2016.